The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours.
 
Howard A. Burris
No Relationships to Disclose
 
Judy Sing-Zan Wang
No Relationships to Disclose
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Tesaro; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Suzanne Fields Jones
No Relationships to Disclose
 
Donald K Strickland
Employment - Sarah Cannon Research Institute
 
Carol Greenlees
No Relationships to Disclose
 
Wolfram Brugger
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Julie Charlton
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Elizabeth Pease
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Alexander MacDonald
Employment - AstraZeneca; GlaxoSmithKline
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline